Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (FO2RWARD-2)

NCT03799627 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.

NCT NCT03799627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03799627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (FO2RWARD-2)
Lead sponsor
Akebia Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2019
Completion date
July 15, 2020
Enrollment
175 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, dialysis-dependent chronic kidney disease